Session Evaluation - Genomics Guiding Therapeutics

Speaker Ratings *

Please rate the presentations skills of each of the speakers.

	Very High	High	Moderate	Low	Very Low
Howard A Burris	Howard A Burris - Very High	Howard A Burris - High	Howard A Burris - Moderate	Howard A Burris - Low	Howard A Burris - Very Low
Stephen C Pieper	Stephen C Pieper - Very High	Stephen C Pieper - High	Stephen C Pieper - Moderate	Stephen C Pieper - Low	Stephen C Pieper - Very Low
Clifford A Hudis	Clifford A Hudis - Very High	Clifford A Hudis - High	Clifford A Hudis - Moderate	Clifford A Hudis - Low	Clifford A Hudis - Very Low
Veda Giri	Veda Giri - Very High	Veda Giri - High	Veda Giri - Moderate	Veda Giri - Low	Veda Giri - Very Low
Ashwin R Sama	Ashwin R Sama - Very High	Ashwin R Sama - High	Ashwin R Sama - Moderate	Ashwin R Sama - Low	Ashwin R Sama - Very Low
Louis M Seiner	Louis M Seiner - Very High	Louis M Seiner - High	Louis M Seiner - Moderate	Louis M Seiner - Low	Louis M Seiner - Very Low
Ralph Zinner	Ralph Zinner - Very High	Ralph Zinner - High	Ralph Zinner - Moderate	Ralph Zinner - Low	Ralph Zinner - Very Low
Kunle Odunsi	Kunle Odunsi - Very High	Kunle Odunsi - High	Kunle Odunsi - Moderate	Kunle Odunsi - Low	Kunle Odunsi - Very Low
Margaret T Kasner	Margaret T Kasner - Very High	Margaret T Kasner - High	Margaret T Kasner - Moderate	Margaret T Kasner - Low	Margaret T Kasner - Very Low
William K Kelly	William K Kelly - Very High	William K Kelly - High	William K Kelly - Moderate	William K Kelly - Low	William K Kelly - Very Low

Comments for Dr Burris

Comments for Dr Peiper

Comments for Dr Hudis

Comments for Dr Giri

Comments for Dr Sama

Comments for Dr Kasner

Comments for Dr Weiner

Comments for Dr Zinner

Comments for Dr Odunsi

Comments for Dr Kelly

Rate the extent to which the session objectives were met *

	Very High	High	Moderate	Low	Very Low	NA
Introduction	Introduction - Very High	Introduction - High	Introduction - Moderate	Introduction - Low	Introduction - Very Low	Introduction - NA
Impact of Genomics on Phase 1 Trials	Impact of Genomics on Phase 1 Trials - Very High	Impact of Genomics on Phase 1 Trials - High	Impact of Genomics on Phase 1 Trials - Moderate	Impact of Genomics on Phase 1 Trials - Low	Impact of Genomics on Phase 1 Trials - Very Low	Impact of Genomics on Phase 1 Trials - NA
Genomically Informed and Personally Precise	Genomically Informed and Personally Precise - Very High	Genomically Informed and Personally Precise - High	Genomically Informed and Personally Precise - Moderate	Genomically Informed and Personally Precise - Low	Genomically Informed and Personally Precise - Very Low	Genomically Informed and Personally Precise - NA
How Genomics Guide Breast Cancer Treatment	How Genomics Guide Breast Cancer Treatment - Very High	How Genomics Guide Breast Cancer Treatment - High	How Genomics Guide Breast Cancer Treatment - Moderate	How Genomics Guide Breast Cancer Treatment - Low	How Genomics Guide Breast Cancer Treatment - Very Low	How Genomics Guide Breast Cancer Treatment - NA
How Genomics Guide Cancer Risk Assessment	How Genomics Guide Cancer Risk Assessment - Very High	How Genomics Guide Cancer Risk Assessment - High	How Genomics Guide Cancer Risk Assessment - Moderate	How Genomics Guide Cancer Risk Assessment - Low	How Genomics Guide Cancer Risk Assessment - Very Low	How Genomics Guide Cancer Risk Assessment - NA
How Genomics Direct Basket Trials	How Genomics Direct Basket Trials - Very High	How Genomics Direct Basket Trials - High	How Genomics Direct Basket Trials - Moderate	How Genomics Direct Basket Trials - Low	How Genomics Direct Basket Trials - Very Low	How Genomics Direct Basket Trials - NA
How Genomics Guide GI Malignancy Treatment	How Genomics Guide GI Malignancy Treatment - Very High	How Genomics Guide GI Malignancy Treatment - High	How Genomics Guide GI Malignancy Treatment - Moderate	How Genomics Guide GI Malignancy Treatment - Low	How Genomics Guide GI Malignancy Treatment - Very Low	How Genomics Guide GI Malignancy Treatment - NA
How Genomics Guide Lung Cancer Treatment	How Genomics Guide Lung Cancer Treatment - Very High	How Genomics Guide Lung Cancer Treatment - High	How Genomics Guide Lung Cancer Treatment - Moderate	How Genomics Guide Lung Cancer Treatment - Low	How Genomics Guide Lung Cancer Treatment - Very Low	How Genomics Guide Lung Cancer Treatment - NA
Panel Discussion	Panel Discussion - Very High	Panel Discussion - High	Panel Discussion - Moderate	Panel Discussion - Low	Panel Discussion - Very Low	Panel Discussion - NA
Impact of Genomics on Immunotherapy	Impact of Genomics on Immunotherapy - Very High	Impact of Genomics on Immunotherapy - High	Impact of Genomics on Immunotherapy - Moderate	Impact of Genomics on Immunotherapy - Low	Impact of Genomics on Immunotherapy - Very Low	Impact of Genomics on Immunotherapy - NA
How Genomics Guide Treatment of Acute Leukemias	How Genomics Guide Treatment of Acute Leukemias - Very High	How Genomics Guide Treatment of Acute Leukemias - High	How Genomics Guide Treatment of Acute Leukemias - Moderate	How Genomics Guide Treatment of Acute Leukemias - Low	How Genomics Guide Treatment of Acute Leukemias - Very Low	How Genomics Guide Treatment of Acute Leukemias - NA
How Genomics Guide Prostate Cancer Treatment	How Genomics Guide Prostate Cancer Treatment - Very High	How Genomics Guide Prostate Cancer Treatment - High	How Genomics Guide Prostate Cancer Treatment - Moderate	How Genomics Guide Prostate Cancer Treatment - Low	How Genomics Guide Prostate Cancer Treatment - Very Low	How Genomics Guide Prostate Cancer Treatment - NA

Comments on Objectives

SKMC Office of CME

Thomas Jefferson University Sidney Kimmel Medical College

Session Evaluation - Genomics Guiding Therapeutics

Credit

Certificate

Course navigation

Thomas Jefferson University Sidney Kimmel Medical College

You are here

Session Evaluation - Genomics Guiding Therapeutics

Credit

Certificate

Course navigation